Management of Atrial Fibrillation in Older Patients by Morbidity Burden: Insights From Get With The Guidelines‐Atrial Fibrillation
Open Access
- 1 December 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 9 (23) , e017024
Abstract
Background: Knowledge is scarce regarding how multimorbidity is associated with therapeutic decisions regarding oral anticoagulants (OACs) in patients with atrial fibrillation. Methods and Results: We conducted a cross‐sectional study of hospitalized patients with atrial fibrillation using the Get With The Guidelines‐Atrial Fibrillation registry from 2013 to 2019. We identified patients ≥65 years and eligible for OAC therapy. Using 16 available comorbidity categories, patients were stratified by morbidity burden. A multivariable logistic regression model was used to determine the odds of receiving OAC prescription at discharge by morbidity burden. We included 34 174 patients with a median (interquartile range) age of 76 (71–83) years, 56.6% women, and 41.9% were not anticoagulated at admission. Of these patients, 38.6% had 0 to 2 comorbidities, 50.7% had 3 to 5 comorbidities, and 10.7% had ≥6 comorbidities. The overall discharge OAC prescription was high (85.6%). The prevalence of patients with multimorbidity increased from 59.7% in 2014 to 64.3% in 2019 ( P trend=0.002). Using 0 to 2 comorbidities as the reference, the adjusted odds ratio (95% CI) of OAC prescription were 0.93 (0.82, 1.05) for patients with 3 to 5 comorbidities and 0.72 (0.60, 0.86) for patients with ≥6 comorbidities. In those with ≥6 comorbidities, the most common reason for nonprescription of OACs were frequent falls/frailty (31.0%). Conclusions: In a contemporary quality‐of‐care database of hospitalized patients with atrial fibrillation eligible for OAC therapy, multimorbidity was common. A higher morbidity burden was associated with a lower odds of OAC prescription. This highlights the need for interventions to improve adherence to guideline‐recommended anticoagulation in multimorbid patients with atrial fibrillation.Keywords
This publication has 41 references indexed in Scilit:
- Frailty in elderly peopleThe Lancet, 2013
- All-cause mortality in 272 186 patients hospitalized with incident atrial fibrillation 1995–2008: a Swedish nationwide long-term case–control studyEuropean Heart Journal, 2013
- Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trialThe Lancet, 2012
- Risk of Falls and Major Bleeds in Patients on Oral Anticoagulation TherapyThe American Journal of Medicine, 2012
- Measures of Multimorbidity and Morbidity Burden for Use in Primary Care and Community Settings: A Systematic Review and GuideThe Annals of Family Medicine, 2012
- Aging with multimorbidity: A systematic review of the literatureAgeing Research Reviews, 2011
- Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic reviewAge and Ageing, 2011
- Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fallThe American Journal of Medicine, 2005
- Common comorbidity scales were similar in their ability to predict health care costs and mortalityJournal of Clinical Epidemiology, 2004
- Risk Factors for Stroke and Efficacy of Antithrombotic Therapy in Atrial FibrillationArchives of internal medicine (1960), 1994